Statins have been known to significantly reduce cardiovascular events in patients with
cardiovascular disease. This review was undertaken to examine the current evidence for the …

Aims (i) To examine the incidence of new onset treated diabetes in patients treated with
different types of statins and (ii) the relationship between the duration and dose of statins …

Objective: Randomised controlled trials (RCTs) indicate that statin therapy has
cardiovascular benefit among patients with type 2 diabetes. Recently, statins were reported …

BACKGROUND: Rosuvastatin and pravastatin have differential hydrophilicity and potency to
inhibit hydroxymethylglutaryl-CoA reductase that may be relevant to changes in adiponectin …

Aims We hypothesised that serum fibroblast growth factor 21 (FGF-21), a novel adipokine
with postulated insulin-sensitizing effects, may be predictive of cardiovascular (CV) events in …

Background Statins reduce cardiovascular risks but increase the risk of new-onset diabetes
(NOD). The aim of this study is to determine what effect, if any, statins have on the risk of …

Background: Statins significantly reduce cardiovascular events in a broad population of
patients with hyperlipidemia. However, a small, but significant risk of new-onset diabetes …

Statins are widely prescribed cholesterol-lowering agents, which have been demonstrated
to significantly reduce cardiovascular morbidity and mortality. However, recent trials have …

Aims: The present study investigated the effects of lipid-lowering therapy with atorvastatin on
skin microvascular function in patients with type 1 diabetes and dyslipidaemia. Methods …

Objective. The aim of the study was to determine the prevalence of cardiometabolic
dysregulations and their somatic treatment regimens in a group of psychiatric patients …